An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 26 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2019.
- 26 Feb 2017 Status changed from not yet recruiting to recruiting.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress